Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G
Institute of Internal Medicine, University of Turin, Italy.
Diabetes. 1994 Mar;43(3):426-9. doi: 10.2337/diab.43.3.426.
Microalbuminuria is associated with an increased risk of cardiovascular disease (CVD) in insulin-dependent diabetes mellitus (IDDM) patients, but the pathophysiological basis of this association is not clear. To see whether or not hemostatic dysfunctions might contribute to explain this association, we measured tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), factor VII activity, plasma fibrinogen, and plasma endothelin-1 (ET-1) in 13 microalbuminuric (albumin excretion rate [AER], 20-200 micrograms/min) and in 13 comparable normoalbuminuric (< 20 micrograms/min) IDDM patients. t-PA and ET-1 were similar in the two groups, whereas PAI-1 activity (5.65 +/- 1.92 vs. 0.85 +/- 0.58 IU/ml, P < 0.05), factor VII (87.85 +/- 4.94 vs. 76.54 +/- 2.31%, P < 0.05), and plasma fibrinogen (3.38 +/- 0.21 vs. 2.65 +/- 0.13 g/l, P < 0.05) were significantly higher in microalbuminuric than in normoalbuminuric patients. Plasma fibrinogen was related to AER (r2 = 0.23, P < 0.05), whereas triglycerides and factor VII were related to PAI-1 (r2 = 0.39, P < 0.001 and r2 = 0.10, P < 0.05). These results suggest that microalbuminuria is associated with a hypercoagulative and hypofibrinolytic state. Hemostatic dysfunctions might be a pathogenetic link between microalbuminuria and CVD.
微量白蛋白尿与胰岛素依赖型糖尿病(IDDM)患者心血管疾病(CVD)风险增加相关,但这种关联的病理生理基础尚不清楚。为了观察止血功能障碍是否可能有助于解释这种关联,我们检测了13例微量白蛋白尿患者(白蛋白排泄率[AER]为20 - 200微克/分钟)和13例可比的正常白蛋白尿患者(<20微克/分钟)的组织纤溶酶原激活物(t-PA)、纤溶酶原激活物抑制剂-1(PAI-1)、因子VII活性、血浆纤维蛋白原和血浆内皮素-1(ET-1)。两组患者的t-PA和ET-1相似,而微量白蛋白尿患者的PAI-1活性(5.65±1.92 vs. 0.85±0.58 IU/ml,P<0.05)、因子VII(87.85±4.94 vs. 76.54±2.31%,P<0.05)和血浆纤维蛋白原(3.38±0.21 vs. 2.65±0.13 g/l,P<0.05)显著高于正常白蛋白尿患者。血浆纤维蛋白原与AER相关(r2 = 0.23,P<0.05),而甘油三酯和因子VII与PAI-1相关(r2 = 0.39,P<0.001和r2 = 0.10,P<0.05)。这些结果表明,微量白蛋白尿与高凝和低纤溶状态相关。止血功能障碍可能是微量白蛋白尿与CVD之间发病机制的联系。